Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation

Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation

BackgroundCostimulatory blockade provides new therapeutic opportunities for ensuring the long-term survival of kidney grafts. The adoption of the novel immunosuppressant Belatacept has been limited, partly due to concerns regarding higher rates and grades of acute rejection in clinical trials. In th...

Full description

Bibliographic Details
Main Authors: Hengcheng Zhang, Zijie Wang, Jiayi Zhang, Zeping Gui, Zhijian Han, Jun Tao, Hao Chen, Li Sun, Shuang Fei, Haiwei Yang, Ruoyun Tan, Anil Chandraker, Min Gu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
kidney transplantation
Belatacept
acute rejection
BTLA
CTLA-4
immunosuppressant
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.618737/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.618737/full

Similar Items